Tag:

GW Pharmaceuticals

Latest Headlines

GW's cannabis-based mouth spray gains Austrian OK for MS spasms

February 7, 2012

British drug developer GW Pharmaceutical will debut its cannabis-based pain therapy Sativex in Austria as a treatment for MS-related spasticity sometime in 2012, following regulatory approval

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

MORE EVENTS

Press Releases

Featured Jobs

Analytical Scientist Job
Yoh - Durham, NC, USA
Pharmacist (Drug Safety and Product Information) Job
Yoh - Durham, NC, USA
Director, Safety Pharmacology and Toxicology
Tesaro - Waltham, MA
Research & Development Chemist
C3 Jian - Marina Del Rey, CA
Pilot Manufacturing Scientist Job
Yoh - Cambridge, MA, USA

GW Pharmaceuticals

Latest Headlines

Latest Headlines

GW's cannabis-based mouth spray gains Austrian OK for MS spasms

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

GW Pharmaceuticals

Latest Headlines

Latest Headlines

GW's cannabis-based mouth spray gains Austrian OK for MS spasms

Related Tags